Uno de los principales objetivos de la ciencia es desarrollar nuevo conocimiento. Sin embargo, éste no sólo debe generarse, también debe comunicarse. Es decir, no publicar nuestros resultados es equivalente a nunca haberlos generado. En este sentido, la publicación de resultados es una de las principales labores y responsabilidades del científico. Existen múltiples razones para hacerlo¹, por ejemplo:

• Promover el avance y aplicación de un nuevo conocimiento
• Generar un efecto positivo (directo o indirecto) en la sociedad
• Recibir otros beneficios relacionados con la mejora de la trayectoria académica, profesional y personal de cada autor

Background: There is a need for information on the current practices of diabetes management to take some actions and improve the attainment of therapeutic goals. Objective. We aimed to describe the attainment of therapeutic targets and late complications of patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus. Material and Methods. In the fourth wave of the International Diabetes Management Practices Study, 1,966 Mexican patients were analyzed (T1D: n=157, 8%; T2D: n=1809, 92%). The cross-sectional phase regarding metabolic profile, current complications, and management are analyzed. Results. Out of T1D patients, 77.6% received insulin alone, and 27.4% had insulin and oral glucose-lowering drugs (OGLD, mostly metformin). Out of T2D patients, 63% received OGLD exclusively (mostly metformin), 4.3% insulin alone, 30.4% OGLD, and insulin, and 2% were on a diet and exercise exclusively. Only 19.7% T1D and 35.9% T2D patients had HbA1c <7% (p=0.01), and only 5.0% of T1D and 3.9% of T2D met the combined therapeutic target of HbA1c <7% + BP <130/80 mmHg + LDL <100 mg/dl. Late diabetes-related complications occurred in 42.7% of T1D and 52.8% of T2D patients, mostly microvascular disease. Macrovascular complications were more frequent in patients with T2D, as compared with T1D (36.8% vs. 16.4%, p<0.001). The number of late complications increased steadily with disease duration, more pronounced in patients with T2D. Conclusions. This study evidences substantial lags in the attainment of clinical goals of patients with diabetes mellitus. There are noticeable differences in the achievement of current therapeutic targets between patients with T1D and T2D in a sample of the Mexican practice.

Allogeneic stem cell transplantation is one of the most immunosuppressive states in transplantation, mainly in the first year post-transplant. In the COVID-19 pandemic, this group of patients is at increased risk of mortality and morbidity due to a more vulnerable immune system. Even with the new vaccines against SARS-CoV-2, the availability to build a vaccine-induced immune response that could protect against the virus infection is unclear as the immune responses are blocked by the immunosuppressive drugs used in these patients (and according to some studies, in patients with hematological malignancy). Based on this background, effective therapies against COVID-19 in patients post-transplant are mandatory. Herein, we report the case of a patient with acute lymphoblastic leukemia (after haploidentical bone marrow transplantation) who successfully responded to COVID-19 pneumonia with the JAK1/2 inhibitor, ruxolitinib.